In a decision delivered last Monday, the U.S. Supreme Court rejected an appeal by Dartmouth College, effectively ending the university’s effort to overturn a previous Federal Circuit declaration. The case involved Dartmouth’s attempt to revive a patent for vitamin B3, which the institution had levied against Elysium Health, a manufacturer of dietary supplements, in a preceding federal case from Delaware.
This latest decision from the Supreme Court follows an escalating legal disagreement between Dartmouth College and Elysium Health regarding the patent eligibility of a certain type of vitamin B3. Unfortunately for Dartmouth, the Federal Circuit’s earlier refusal to revive the patent in question has now been reinforced by the Supreme Court’s ruling.
As one of the nation’s foremost suppliers of dietary supplements, Elysium Health has been at the centre of this suit, as the defendant in Dartmouth’s patent complaint.
Dartmouth’s rejected bid for Supreme Court review marks a significant point in this ongoing patent eligibility controversy. The details and potential implications of this legal clash will undoubtedly reverberate throughout the world of business and intellectual property law.
To learn more about this case and its implications, you can read the full discussion about the legal precedent and further context on Law360.